Navigation Links
NYU Langone Medical Center's tip sheet to the 44th annual meeting of ASCO
Date:5/16/2008

with a new type of agent that releases molecules that have been silenced during cancer progression.


A Potential New Melanoma Cancer Vaccine

Abstract # 3044 : KBMA Listeria monocytogenes is an effective antigen loading platform for dendritic cell-mediated induction of anti-tumor immunity
NYU Cancer Institutes Nina Bhardwaj, M.D., professor of medicine, pathology, dermatology; director, tumor vaccine program, at NYU Langone Medical Center
NYU Cancer Institutes Mojca Skoberne, Ph.D. researcher, at NYU Langone Medical Center

NYU Langone Medical Center researchers report that killed but metabolically active recombinant Listeria monocytogenes, a Gram-positive bacterium, may provide a platform for novel melanoma vaccines. Melanoma is the deadliest form of skin cancer, and will afflict some 62,480 people in the United States this year. The researchers demonstrate in an animal model and in vitro human cell cultures that immune cells were called into action by tumor proteins expressed by the bacterium. The finding suggests that the genetically engineered bacterium may be used to bolster the immune response against a resurgence of the deadly cancer. Clinical trials are underway at the medical center using a melanoma vaccine that employs powerful immune cells called dendritic cells. The bacterial approach to activate the dendritic cells may provide a new avenue for developing a more powerful cancer vaccine.


Early Results from a Chemotherapy Trial for Metastatic Melanoma

A phase I/II study to determine the feasibility and efficacy of the triple combination of oblimersen (OBL), abraxane (ABX), and temozolomide (TMZ) in metastatic melanoma and normal LDH
NYU Cancer Institutes Anna C Pavlick, D.O., assistant professor of medicine and dermatology at NYU Langone Medical Center; co-program leader, melanoma research program

Researchers at NYU Langone Medical Center report
'/>"/>

Contact: Jennifer Berman
Jennifer.Berman@nyumc.org
212-404-3555
NYU Langone Medical Center / New York University School of Medicine
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. Medical College of Wisconsin researchers identify proteins that help develop mammalian hearts
2. Select Medical Corporation Announces Results for First Quarter Ended March 31, 2008
3. The 2008 AMIA Spring Congress to Showcase Best Practices and Innovations in Biomedical and Health Informatics Research and Education
4. Americans must consider cost and effectiveness when comparing and choosing medical interventions
5. AGA Medical Corporation Receives CE Mark Approval for the AMPLATZER(R) Vascular Plug III
6. Nonin(R) Medical Pioneers First Interoperable, Wireless Fingertip Pulse Oximeter
7. CRH Medical Corporation opens Center in New York
8. Mindray Medical Completes Acquisition of Datascopes Patient Monitoring Business
9. RNC RESPONSE TO OBAMA COMMENTS ON MEDICAL MARIJUANA LAWS
10. LMS Medical Sees Fiscal 2008 Revenue Jump 72% Over F07 - Q4/F08 Revenue Hits New Record
11. UNICEF Rushing Medical Supplies, Tents, Clean Water to Children Affected by Powerful Earthquake in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... 01, 2014 The European gas chromatography systems ... analysis and forecast of revenue. The gas chromatography systems market ... is estimated to grow to around $247.6 million by 2018, ... Browse through the TOC of the European gas chromatography systems ... This also provides a glimpse of the segmentation of gas ...
(Date:8/1/2014)... According to a new market research report of ... Types, Applications (Automotive, Petrochemical, Consumer Utility, Glass, and Aerospace ... - Analysis & Forecast to 2010 - 2020", published ... to $1.42 Billion by 2020 at a CAGR of ... grow to $238.17 Million by 2020 at a CAGR ...
(Date:8/1/2014)... Society of America (GSA) the nation,s ... aging has chosen J. Jill Suitor, PhD, ... the Distinguished Career Contribution to Gerontology Award. , ... individual whose theoretical contributions have helped bring about ... original and elegant research designs addressing a significant ...
(Date:8/1/2014)... of America (GSA) the nation,s largest ... has chosen Madonna Harrington Meyer, PhD, of ... University of Luxembourg; and Philipp Hessel, MA, MSc, ... of Economics and Political Science as the 2014 ... , These distinguished honors recognize insightful and innovative ...
(Date:8/1/2014)... August 01, 2014 Lifeinsurancenomedicalexam.info has ... life insurance for clients who have high cholesterol levels. ... still find and qualify for no medical exam life ... requiring any background medical check-ups. , Since there are ... cholesterol level will qualify in just a few minutes. ...
Breaking Medicine News(10 mins):Health News:European Gas Chromatography (GC) Systems Market is Expected to Reach $247.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:European Gas Chromatography (GC) Systems Market is Expected to Reach $247.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:European Gas Chromatography (GC) Systems Market is Expected to Reach $247.6 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Thermocouples Market worth $1.42 Billion & High End Optical Pyrometers Market worth $ 238.17 Million by 2020 2Health News:Thermocouples Market worth $1.42 Billion & High End Optical Pyrometers Market worth $ 238.17 Million by 2020 3Health News:Thermocouples Market worth $1.42 Billion & High End Optical Pyrometers Market worth $ 238.17 Million by 2020 4Health News:Suitor to receive GSA's 2014 Distinguished Career Contribution to Gerontology Award 2Health News:Harrington Meyer, Leist, Hessel, Avendano to receive GSA's 2014 Kalish awards 2Health News:No Exam Life Insurance - Coverage for Clients Who Have High Cholesterol 2
... ... educational stories, NEW YORK, May 12 ... Gamble Pharmaceuticals (P&G), has,selected seven winners for the Celebrating UC Success ... by ulcerative,colitis. Winners, stories reflect a wide variety of experiences with,ulcerative ...
... 12 FutureScripts(R), the premier,pharmacy benefit manager in ... . The website is a valuable tool for ... find key,information about the drugs on FutureScripts, formulary, ... "The new website allows our customers to find ...
... in French . , Montreal, May 12, 2008 ... in some cases, emotional and physical pain can linger for ... Universit de Montral graduate student Emma Duerden is inviting amputees ... study. , Our main goal is to better understand why ...
... homeless youth suggests that treating substance abuse and mental health ... the streets. , Instead, researchers found that creating more opportunities ... factors in reducing homelessness. , A study of 180 ... most social stability, such as those who attended school more ...
... is Disability Insurance Awareness Month; LIFE Foundation Reviews Common, Misconceptions to Encourage ... ... Needs, ARLINGTON, Va., May 12 If you were ... yourself,financially? The results of a new survey released today by the nonprofit,LIFE ...
... uncover ... system abuse, HORSEHEADS, N.Y., May ... in 2007. With so many recipients and,providers involved, the New York State ... abuse., Over the last two years, Salient Corporation, provider of the ...
Cached Medicine News:Health News:UPDATE: Celebrating UC Success Announces Essay Contest Winners 2Health News:UPDATE: Celebrating UC Success Announces Essay Contest Winners 3Health News:UPDATE: Celebrating UC Success Announces Essay Contest Winners 4Health News:UPDATE: Celebrating UC Success Announces Essay Contest Winners 5Health News:UPDATE: Celebrating UC Success Announces Essay Contest Winners 6Health News:Pharmacy Benefit Manager FutureScripts(R) Launches New Website 2Health News:Pharmacy Benefit Manager FutureScripts(R) Launches New Website 3Health News:Homeless youth need more than treatment for substance abuse, study says 2Health News:Homeless youth need more than treatment for substance abuse, study says 3Health News:New Survey Finds Overwhelming Majority of Working Americans Not Financially Prepared for Disability, Would Rely on Sources Other than Themselves for Support 2Health News:New Survey Finds Overwhelming Majority of Working Americans Not Financially Prepared for Disability, Would Rely on Sources Other than Themselves for Support 3Health News:New Survey Finds Overwhelming Majority of Working Americans Not Financially Prepared for Disability, Would Rely on Sources Other than Themselves for Support 4Health News:Salient Corporation's Performance Management Solution Helps NY State Counties Identify Medicaid Fraud, Waste, and Abuse 2
(Date:7/31/2014)... , July 31, 2014 Lazarus Effect, ... novel interventional devices to facilitate removal of blood clots, ... from the financing will support EU commercialization of several ... for the Lazarus ReCover™ and Lazarus Cover™ in ... financing reflects investor confidence in the value of our ...
(Date:7/31/2014)... Catylix, Inc. ( Burbank, California ... California ) announced today the formation of ... fluorination products and related chemistry. Developing ... use of substituents that are chemically stable, resistant ... improve binding and bioavailability. Fluorinated functional groups are ...
(Date:7/31/2014)... -- Zacks.com announces the list of stocks featured in the Analyst ... latest news and events impacting stocks and the financial markets. ... BIIB - Free Report ), Gilead (Nasdaq: GILD - ... Report ), AbbVie (NYSE: ABBV - Free Report ) ... Today, Zacks is promoting its ,Buy, stock recommendations. ...
Breaking Medicine Technology:Lazarus Effect Closes $5 Million Financing 2Catylix, Inc. and Aspira Scientific Announce Joint Venture to Commercialize New Fluorination Technologies 2The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 2The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 3The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 4The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 5The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 6
... Phase III,clinical trial evaluating the efficacy and safety ... of postmenopausal osteoporosis were,presented at the American Society ... In the non-inferiority study comparing risedronate 150,mg once ... sodium,tablets)] increases in bone mineral density (BMD) were ...
... Sept. 19 Rockwell Medical,Technologies, Inc. (Nasdaq: ... and,developer of concentrates and specialty pharmaceuticals focused ... that it has commenced,enrollment in its Phase ... a physiological iron-maintenance therapy drug. The ...
Cached Medicine Technology:New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 2New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 3New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 4New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 5New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 6Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study 2Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study 3Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study 4
... designed to validate HDL cholesterol plus other ... This control is compatible with most major ... Synchron and Vitros. HDL values are given ... methods: Dextran Sulfate 50,000 MW. Apolipoprotein A-1 ...
... is intended as a means ... ethanol assay methods. This ready-to-use, ... clinically significant levels of ammonia ... provided for the following instruments: ...
... This unassayed control is intended ... manual and automated assay methods ... oxalate in human urine samples. ... requiring no reconstitution. This control ...
... Microbumin is a two-level control ... Clinitek Microalbumin Reagent Strips and Roche ... also suitable for turbidimetric immunoassays using ... and DCA 2000, Cobas, Diasorin SPQ ...
Medicine Products: